News
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
January 17, 2023
- Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox...
Read more
MIMETAS Elected Most Innovative Company of the Netherlands
November 02, 2022
Mimetas is the winner of the Dutch Innovation Award 2022.
Read more
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
October 18, 2022
Synaffix B.V. today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® m...
Read more
Professor Melief to receive 2022 SITC Pedro J. Romero Award
September 08, 2022
Professor Melief to receive 2022 SITC Pedro J. Romero Award
Read more
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
September 07, 2022
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
July 15, 2022
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy
Read more
FDA Accepts Byondis' BLA for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
July 12, 2022
Byondis acquired the technology for the development of its anti-HER2 ADC drug from Aglaia's portfolio company Syntarga in 2010.
Read more
In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed
June 16, 2022
Scientists from MIMETAS introduce a platform for routine grafting of liver and other tissues on an in vitro grown microvascular...
Read more
Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting
May 27, 2022
ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficac...
Read more
New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non- Invasive Imaging
May 04, 2022
Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other di...
Read more
MIMETAS Expands Adult Stem Cell Organoid License to All Organs
May 03, 2022
MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has expanded its license to the HUB...
Read more
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
April 14, 2022
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
Read more
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting
February 17, 2022
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic...
Read more
Modeling ischemic stroke in a triculture neurovascular unit on-a-chip
December 15, 2021
Scientists from MIMETAS introduce a new neurovascular unit on-a-chip model to study ischemic events in the human brain.
Read more
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
December 10, 2021
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met
- The triplet combination sho...
Read more
InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors
December 02, 2021
IND approval enables clinical trial advancement and enrollment of
dose expansion cohorts in the US
Read more
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
October 19, 2021
-- Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA's preclinical pipeline and accelerate clini...
Read more
InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board
October 12, 2021
Appointment of Andrea van Elsas as a new member of the Company's Supervisory Board.
Read more
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A
October 07, 2021
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A
Read more
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021
- Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treate...
Read more
